%PDF-1.3 % 2 0 obj stream hn@~JlbDHuc[RvCT4Jz`O7Jy{$p~@I,/Gpd&[IUe ;nR+Z; v&N}'Eh.yL>MT3y3OdqzjuJOk~h&+j7sv2nmasVV?^L,@}ieiPw}@t05wtm5[Mruk2un](W;4,z|[V>>wB4"xf~X) =*t $$BS#5*o ^b?.sJR[e ]BPkllG*v=QfG~duX=~"MK8"DYd-4bEssISiOv$6ZSn'm2]?ZKd?%R-oZi;:> (L#L S, x*fxV[GgF@ MiiRz-X%$6Z;PX0'^_beBGr$w*Kl3Iew/s{34kpi by-%O ,y"-Y&yqeGV31Bx$sMot=!z6KyglDIBMe&+*F1%(KT(Q '!lDI$bEbE$Zf"VHVt?KII{~!J DntndRWIwEoP28C!QAH PmRzdUUH*3.6G/Re@2@5X|^)'qE@d/iJgY%N/u4Kt9%}KdS,Ua5#Cp'2Thr*FKhz4F/ NeqpD"R$fClyo("cKAd@[4)Esbd,u:5la2-Kz UB9K@H"M8FCh%-e$EQ?Fap|@EhnA`~KL^Kr2VAqa:uo~jIede`$2bz4#i}~gICE*aELm]i wIS$PH};UahVKMPn T")Vy ?FDSCi(.Wf, ? )_+7%v< ArOmnz4v0 ("-/@%!&g:}F3*V_DfkX8fBU,e`lQ}a$hRYeb![ Ll+ls'SSO5 n}O{)lWif( TDZ#T@Mo_lWciWme"Hm|%iX#W4GLHngl-qU!pL?d|[0]l9O49~)aqHC[fWVTgIX^CcxogsQ;'sq_%`.jII)n#j'l,X'gO Mu?#"maZ0a'N1 0U|*{X;wXll}L q57(@Rm[RjDhWWm[hOn{l +YVwPR0I~y)9#Nx?^TNLIO`G*(xqH`NV2Nd3K0XU)8y2W;sC+ [7b|CI< Iw 8?#J eP ~{y{Tj"XG?M'/(1 ?PuEK ^0(rkl{~U_r!>_ILtP;#wtZzqdM*J &`y%mu5!e8Z^|677/`S4.707B 1 m{+?Vm0LE zxe|594["@+},ki&9]npAwnJZ`MM7v@ ,ll*@mL a_I"*aM,Y fzc_:|)'^mA1(-i/B3l"u'4m hI?]!GOVBhK}L9B$L FLX9/cU`j,| (#I}NNQ?,) n.[$2D/B e3s0 Kn~c@-(a^%,.nhr+Yk1/>}GQaB/J>W!ZT#=*?=qSVz-5HjT7GL!T;J"2uOn)o~d$_c*?~H#eFL H/NON*F M)#LMoFEKJ'BVN?w".T{ZmZ;s8}@uiUUb" hH g:F/CXj=_Di`] l!5!$j*'&qQsJ7PfE2G"B_0ziMm 5Sw lMP#KbHjOticjVuVGR9&td1b[-Z8LCY'dLm.9.MvUHj7C-d$GpP75y/FE**8DgYSIU>,3w[W ,g"HR`1q3"6e>Y>0XaD[CSS6_%RRq`+J3[Hj4Wu6z933!cnT8P`6t]D$k:d%6K@# Xv@I )4U u6[ ?:=O]o*tof%~WT(f i="C v+! jE+n;n_zN[bVbR[?~ )q)V'%S;f}-u;g=z{NheT=p+8Oj?*D+yCX o U&7JRU4 @)~Rt%q~v%}q'QQMM?_qIUb $ x.J5zVvOHkHCig T[DaEvjed]eoAj~kbg;&Z5jDW(I 7|-XrDr ,"cILTBDo}40G:S=Mo|yB`HhTf5%%rfB(/)55_qT=>VQB(;anr/8Ynyt^ IGp S1z`Hqj]4q# Ro6Dx|80!vrcS_mA|m>Gz@g< > endobj 79 0 obj endobj 81 0 obj endobj 82 0 obj endobj 83 0 obj endobj 84 0 obj endobj 85 0 obj endobj 86 0 obj endobj 87 0 obj endobj 88 0 obj endobj 89 0 obj endobj 90 0 obj endobj 91 0 obj endobj 92 0 obj endobj 93 0 obj endobj 94 0 obj endobj 95 0 obj endobj 96 0 obj endobj 97 0 obj endobj 98 0 obj stream h[vF;?/9"8%sls8(y}}l}UH93FJw^.W1_t.4^wWX|5U)U*W< ]MWy"M2Zac3+}ZF'l.7fMKG}I/7%1/O3G3z.~WK6sWe6]}ChxT^)iX 0'tufs+'r4a(jJf< Zm/~M)BGVY?zwyU>A;Tt&F}Za2jwE]6nObTGNxVYt'p5=9 Cl?H&4JX`tAy.BNEXXPOEQC(!'k1`}*Yl.6MrfMA-3s%OpJ7qtu8Zv3f$[(LD3299q9N`'tg*arCd0M8}`qEZ!:;(eXzT-JFWZNg@d}$>5@t9M7su%Gop,9> 03BC"JQ)WGo0C]N`'SSR0C?fY}f`b5@M{g!KG)">w?|_o~)HGZ>z|>HO=~;UG6 Vgan}&OPOw>{O~)>F';&vbV%$)oXOX{^=q_=j[vGa'cpmGe.iT>R|uU;sIcNl-B@&7@*8_%9C($2S]~*AQM|)S=_0iqJbKa dtM:Z#MroN8j;(+x;+J00BHJU Jx'@dk@/ ,NwT(7y(tJ(A6.I!>NQ5b]m>#gUb @)9Gsoy>/BE:E9Rl2o.CfrhqM1 %zI6ugb`1 2 n H!u6 Sh9#PXW_$6=2 'Sme~ C77b*aW69rW@N7/GT5Gp$hL~{aKSVm!< NU~LeR:qg?QD21,R''Z~0KJzUd".Vg" T-( h$N>A4/ xM 3C]B#4&bL8#(DSxF& uL1W&AysY0ORO0B%UW8bt$ 7$Zl3+7 cg88xqeM*0b#I# cDR~c@+:HT9N^8D/7cY6a%Ibrl4TPQ`;T[daCr>d;y-e!U-rDP(.d>h6)VEn=&Z … Continue reading →

Journal of Hematology & Oncology20125:19 DOI: 10.1186/1756-8722-5-19 Wang et al.; licensee BioMed Central Ltd.2012 Received: 30January2012 Accepted: 16February2012 Published: 30April2012 Mesenchymal stem cells (MSC) have generated a great amount of enthusiasm over the past decade as a novel therapeutic paradigm for a variety of diseases. Currently, MSC based clinical trials have been conducted for at least 12 kinds of pathological conditions, with many completed trials demonstrating the safety and efficacy. This review provides an overview of the recent clinical findings related to MSC therapeutic effects. Roles of MSCs in clinical trials conducted to treat graft-versus-host-disease (GVHD) and cardiovascular diseases are highlighted. Clinical application of MSC are mainly attributed to their important four biological properties- the ability to home to sites of inflammation following tissue injury when injected intravenously; to differentiate into various cell types; to secrete multiple bioactive molecules capable of stimulating recovery of injured cells and inhibiting inflammation and to perform immunomodulatory functions. Here, we will discuss these four properties. Moreover, the issues surrounding clinical grade MSCs and principles for MSC therapeutic approaches are also addressed on the transition of MSCs therapy from bench side to bedside. The online version of this article (doi:10.1186/1756-8722-5-19) contains supplementary material, which is … Continue reading →

Mesenchymal stem cells are the adult stem cells.Mesenchymal stem cells are of various types such as monocytes, adipocytes, osteocytes and chondrocytes. Mesenchymal stem cells main function is to replace or repair damage tissue. In addition, mesenchymal stem cells have high potential for tissue repair. Mesenchymal stem cells are isolated from other tissues such as fallopian tube, cord blood, fetal liver, peripheral blood and fetal lung. Mesenchymal stem cells are renewable source to substitute tissue and cells to treat disabilities and diseases. North America dominates the global market for mesenchymal stem cell due to large number of aging population and increasing incidence of cancers. Asia is expected to show high growth rates in the next five years in the global mesenchymal stem cell market. China and India are expected to be the fastest growing mesenchymal stem cell markets in Asia-Pacific region. Some of the key driving forces for mesenchymal stem cell market in emerging countries are large pool of patients and rising government funding and support. Interested in report: Please follow the below links to meet your requirements; Request for the Report Brochure:http://www.persistencemarketresearch.com/samples/3309 In recent times there is increased use of mesenchymal stem cell due to increasing aging population. Rising incidence … Continue reading →